Abstract:Objective: Colorectal cancer (CRC) is the third cause of expected cancer deaths both in men and women in the U.S. and the third most commonly diagnosed cancer in China Targeted therapy has been proven to improve overall survival for unresectable metastatic CRC. But the location of the primary tumor or the presence of various core driver gene mutations that confer resistance may limit the utility of targeted therapy. Therefore, it is of great significance to further elucidate novel mechanisms of invasion and metastasis of CRC and find potential novel therapeutic targets. Protein Kinase C Delta (PKC delta) plays an important role in various diseases, including tumors. In CRC, the function of PKC delta on proliferation and differentiation is mostly studied but various research results were reported. Therefore, the role of PKC delta in CRC needs to be further studied, especially in tumor invasion and metastasis in CRC which few studies have looked into.Methods: The expression of PRKCD was analyzed by the Genotype-Tissue Expression (GTEx) and The Cancer Genome Atlas (TCGA) databases and Immunohistochemical (IHC). Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) enrichment analysis were used to explore the biological functions and pathways related to PRKCD. Lentivirus transfection was used to construct CRC cell lines with overexpression and knock-down of PKC delta or N-myc Downstream Regulated Gene 1 (NDRG1). Cell invasion and migration assay, wound healing assay were used to detect the function of PKC delta and NDRG1 in the invasion and migration of cells. Flow cytometry analysis was used to detect the influence of PKC delta on the CRC cell cycles .Immunofluorescence histochemistry ,Immunoprecipitation Assay and qPCR were used to detect the relationship of PKC delta and NDRG1. Xenograft model was used to verify the role of PKC delta in vivo.Results: PKC delta is overexpressed in CRC and could promote Epithelial-Mesenchymal Transition (EMT) and the invasion and migration of CRC in vitro. We confirmed that PKC delta and the tumor suppressor factor NDRG1 had a co-localization relationship in CRC. PKC delta inhibited NDRG1 transcription and protein expression. Overexpressing NDRG1 could inhibit the function of PKC delta in promoting tumor invasion and migration. PKC delta could regulate c-Myc, one transcription factor of NDRG1, to down-regulate NDRG1. In vivo, overexpressing PKC delta could promote xenograft growth and volume. Thus, our results showed that PKC delta reduced the expression of NDRG1 through c-Myc, promoting the invasion and migration of CRC through promoting EMT.Conclusion: The increased expression of PKC delta in CRC tumor tissue could promote the invasion and migration of tumor cells, and one of the mechanisms may be regulating c-Myc to inhibit the expression of NDRG1 and promote EMT.

The Expression Profiles and Clinical Significance of PKM2 and Notch1 in Colorectal Cancer

Pyruvate Kinase Type M2 is Upregulated in Colorectal Cancer and Promotes Proliferation and Migration of Colon Cancer Cells.

The ratio of PKM1/PKM2 is the key factor affecting the glucose metabolism and biological function of colorectal cancer cells

Cooperation of SRPK2, Numb and P53 in the Malignant Biology and Chemosensitivity of Colorectal Cancer

Efficacy and mechanism of combination of oxaliplatin with PKM2 knockdown in colorectal cancer

Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics

PKCδ promotes the invasion and migration of colorectal cancer through c-myc/NDRG1 pathway

PKC delta promotes the invasion and migration of colorectal cancer through c-myc/NDRG1 pathway

Identification of Genomic Alterations and Associated Transcriptomic Profiling Reveal the Prognostic Significance of MMP14 and PKM2 in Patients with Pancreatic Cancer.

Mitotic checkpoint kinase Mps1/TTK predicts prognosis of colon cancer patients and regulates tumor proliferation and differentiation via PKCα/ERK1/2 and PI3K/Akt pathway

Correlation of Nrf2, Nqo1, Mrp1, Cmyc and P53 in Colorectal Cancer and Their Relationships to Clinicopathologic Features and Survival

The Role of KDM2B and EZH2 in Regulating the Stemness in Colorectal Cancer Through the PI3K/AKT Pathway

PKM2 Upregulation Promotes Malignancy and Indicates Poor Prognosis for Intrahepatic Cholangiocarcinoma.

Exploring the Expression and the Prognosis of Mismatch Repair Protein and PD-L1 in Colorectal Cancer

PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer

Identification of PFKFB3 as a key factor in the development of colorectal cancer and immunotherapy resistance

Comprehensive Pan-cancer Analysis of CMPK2 as Biomarker and Prognostic Indicator for Immunotherapy

KMT2A Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer

Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells

PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma

Phosphorylase Kinase Β Affects Colorectal Cancer Cell Growth and Represents a Novel Prognostic Biomarker.